Peretinoin, formerly known as NIK-333 , orally bioavailable, acyclic retinoid with potential antineoplastic and chemopreventive activities. Peretinoin binds to and activates nuclear retinoic acid receptors (RAR), which in turn recruit coactivator proteins and promote, with other transcriptional complexes, the transcription of target genes. As a result, this agent may modulate the expression of genes involved in the regulation of cell proliferation, cell differentiation, and apoptosis of both normal and tumor cells. References: Okusaka T, Ueno H, Ikeda M, Morizane C. Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res. 2011 Jun;41(6):542-52. doi: 10.1111/j.1872-034X.2011.00800.x. Epub 2011 Apr 19. PubMed PMID: 21501352.

纯度：≥98%

CAS：81485-25-8